DÄ internationalArchive33/2007Genetically Determined Low Cholesterol and Its Implications for Prevention

Review article

Genetically Determined Low Cholesterol and Its Implications for Prevention

Dtsch Arztebl 2007; 104(33): A-2274

Windler, E; Evans, D; Rinninger, F; Beil, F

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD: Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000; 284: 311–8. MEDLINE
2. Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants from 14 randomised trials of tatins. Lancet 2005; 366: 1267–78. MEDLINE
3. Willich SN: Randomisierte kontrollierte Studien – Pragmatische Ansätze erforderlich. Dtsch Arztebl 103(39): A 2524–9. VOLLTEXT
4. Pedersen TR, Wilhelmsen L, Faergeman O et al.: Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 2000; 86: 257–62. MEDLINE
5. Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega GL, Cohen JC, Hobbs HH: A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 2006; 78: 410–22. MEDLINE
6. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005; 37: 161–5 [Erratum, Nat Genet 2005; 37: 328]. MEDLINE
7. Horton JD, Cohen JC, Hobbs HH: Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 2007; 32: 71–7. MEDLINE
8. Cameron J, Holla OL, Ranheim T, Kulseth MA, Berge KE, Leren TP: Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet 2006; 15: 1551–8. MEDLINE
9. Lagace TA, Curtis DE, Garuti R et al.: Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006; 116: 2995–3005. MEDLINE
10. Evans D, Beil FU: The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women. BMC Med Genet 2006; 7: 66. MEDLINE
11. Tuakli-Wosornu Y, Zhao Z, Lagace T, Horton J, Cohen JC, Hobbs HH: Genetic deficiency of proprotein convertase subtilisin/kexin 9: identification of a compound heterozygote with no PCSK9. Circulation 2006; 114 (Suppl. II): 197.
12. Cohen JC, Boerwinkle E, Mosley TH, Hobbs H: Sequence variations in PCSK9, low LDL and protection against coronary heart disease. N Engl J Med 2006; 354: 1264–72. MEDLINE
13. Brown MS, Goldstein JL: Biomedicine. Lowering LDL – not only how low, but how long? Science 2006; 311: 1721–3. MEDLINE
14. Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004; 24: 1454–9. MEDLINE